|
Session 101
Poster Abstracts
Clinical Pharmacology of Entry Inhibitors
Tuesday, 1 - 4 pm
Poster Hall |
569
 |
Pharmacokinetic Interaction between AMD11070 and Substrates of CYP3A4 and 2D6 Enzymes in Healthy Volunteers
M Nyunt1, S Becker2, R MacFarland2, S Everts1, P Chee2, R Scarborough2, and Craig Hendrix*1
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US and 2AnorMED Inc, Langley, Canada |
570
|
Ritonavir Increases Concentrations of the CXCR4 Antagonist AMD070 in Healthy Volunteers
Ying-Jun Cao*1, C Flexner1, S Dunaway2, J G Park3, K Klingman4, I Wiggins1, J Conley2, C Radebaugh1, S Becker5, C Hendrix1, and the A5191 Study Team
1Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2Univ of Washington Harborview Med Ctr, Seattle, US; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Div of AIDS, NIAID, NIH, Bethesda, MD, US; and 5AnorMED Inc, Langley, Canada |
571
|
Pharmacokinetics of AMD11070, a CXCR4 Antagonist, in HIV-infected Patients Carrying X4-tropic Virus
Marta Boffito*1, G Moyle1, R Wong2, P Chee2, R MacFarland2, G Calandra2, G Bridger2, and S Becker2
1Chelsea and Westminster Hosp, London, UK and 2AnorMED Inc, Langley, Canada |
572
|
Enfuvirtide Does Not Require Dose-adjustment in Patients with Chronic Renal Failure: The Results of a Pharmacokinetic Study of Enfuvirtide in HIV-1-infected Patients with Impaired Renal Function (NP17586)
Pablo Tebas*1, N Bellos2, C Lucasti3, G Richmond4, E Godofsky5, I Patel6, N Buss7, Y Y Chiu6, L Rowell8, and M Salgo6
1Univ of Pennsylvania, Philadelphia, US; 2Southwest Infectious Disease Assoc, Dallas, TX, US; 3South Jersey Infectious Disease, Somers Point, NJ, US; 4North Broward Hosp District, Ft Lauderdale, FL, US; 5Bach & Godofsky, Bradenton, FL, US; 6Roche, Nutley, NJ, US; 7Roche, Basel, Switzerland; and 8Roche, Welwyn, UK |
|
